http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#Head
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#assertion
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#provenance
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#pubinfo
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#assertion
http://purl.obolibrary.org/obo/DOID_13884
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_13884
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00343
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#association
http://www.w3.org/2000/01/rdf-schema#label
"Diltiazem hydrochloride injection is contraindicated in: Patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker. Patients with second- or third-degree AV block except in the presence of functioning ventricular pacemaker. Patients with severe hypotension or cardiogenic shock. Patients who have demonstrated hypersensitivity to the drug. Intravenous diltiazem and intravenous beta-blockers should not be administered together or in close proximity (within a few hours). Patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in WPW syndrome or short PR syndrome. As with other agents which slow AV nodal conduction and do not prolong the refractoriness of the accessory pathway (eg, verapamil, digoxin), in rare instances patients in atrial fibrillation or atrial flutter associated with an accessory bypass tract may experience a potentially life-threatening increase in heart rate accompanied by hypotension when treated with diltiazem hydrochloride injection. As such, the initial use of diltiazem hydrochloride injection should be, if possible, in a setting where monitoring and resuscitation capabilities, including DC cardioversion/defibrillation, are present (see OVERDOSAGE Patients with ventricular tachycardia. Administration of other calcium channel blockers to patients with wide complex tachycardia (QRS >= 0.12 seconds) has resulted in hemodynamic deterioration and ventricular fibrillation. It is important that an accurate pretreatment diagnosis distinguish wide complex QRS tachycardia of supraventricular origin from that of ventricular origin prior to administration of diltiazem hydrochloride injection."
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#association
https://w3id.org/biolink/vocab/relation
https://schema.org/MedicalContraindication
https://identifiers.org/drugbank:DB00343
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#provenance
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#pubinfo
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#sig
http://purl.org/nanopub/x/hasSignature
GM1ebHORQSOLl0aXAdpMD9ZSDIBqY6ZVfNwWF1g37P6NzKhLxzAyywrpzAFG4/KbSCbRaBX/UzBhDAEMqh6H3dC1D+bMZ7JNj0NFtzWrJxVgbP336vDODnxNeOZ2B9EYjPLcxAg8yyG43/T4RSt2Vto3p5IfVUcFZwhNJUIuT0M=
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo
http://purl.org/dc/terms/created
2021-08-23T12:31:18.871+02:00
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY